Company creation
Building around breakthrough science.
We work with scientists and entrepreneurs to define the product strategy, establish the company, assemble leadership and finance its path towards clinical validation.
Investment approach
Scientific judgment.
Investment discipline.
We invest in early-stage therapeutics through two complementary routes: backing existing companies and creating new ones around exceptional science.
We look for therapeutic ideas with a clear biological rationale, a credible path to patients and the potential to change the standard of care.
Early-stage biotech investing requires more than identifying interesting science. It requires choosing the right product hypothesis, understanding what evidence will change the risk profile and building an organisation able to execute against that plan.
Our role is to bring scientific assessment, capital, governance and an international network to those decisions — whether we meet a company at formation or invest in an established team.
The route may differ. The investment standard does not.
How we invest
Two starting points. A shared ambition.
We adapt our role to the opportunity rather than forcing every investment into the same model.
Direct investment
Backing teams already in motion.
We invest in existing biotech companies with differentiated science, strong leadership and a development plan where our specialist capital can accelerate progress.
Decision framework
From signal to investment conviction.
01
Discover
Academic relationships, entrepreneur networks, the international scientific community and AI-enabled scouting broaden the opportunity set.
02
Interrogate
We test the therapeutic hypothesis, evidence quality, intellectual property, product profile and translational strategy.
03
Define
We identify the value-creating milestones and the capital, capabilities and organisation required to reach them.
04
Invest
We structure investments around a rigorous development plan and align around the decisions that matter most.
05
Advance
We support strategy, governance, follow-on financing, organisational development and business development as programmes progress.
Start a conversation